The Relative Strength (RS) Rating for Apellis Pharmaceuticals jumped into a new percentile Wednesday, with an increase from 77 to 81.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
History shows that the best stocks often have an 80 or higher RS Rating as they launch their biggest price moves.
Apellis Pharmaceuticals is not currently showing a potential buy point. See if the stock goes on to form a promising consolidation that could launch a new move.
The company showed 0% earnings growth in its most recent report, while sales growth came in at -11%.
Apellis Pharmaceuticals holds the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
